The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Promoter hypermethylation of p15INK 4 B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early‐stage patients
Abstract
The propensity of myelodysplastic syndrome (MDS) to transform into acute myeloid leukemia (AML) suggests the existence of common pathogenic components for these malignancies. Here, four genes implicated in the development of AML were examined for promoter CpG island hypermethylation in cells from 37 patients with different stages of MDS. Aberrant methylation was detected by polymerase chain reaction amplification of bisulfite‐treated DNA followed by denaturing gradient gel electrophoresis. The highest rate of methylation was found for p15INK 4 B (51%), followed by HIC1 (32%), CDH1 (27%), and ER (19%). Concurrent hypermethylation of ≥3 genes was more frequent in advanced compared with early‐stage MDS (P ≤ 0.05), and hypermethylation of p15INK 4 B was associated with leukemic transformation in early MDS (P ≤ 0.05). The median overall survival was 17 months for cases showing hypermethylation of ≥1 genes vs. 67 months for cases without hypermethylation (P = 0.002). Specifically, promoter hypermethylation identified a subgroup of early MDS with a particularly poor prognosis (median overall survival 20 months vs. 102 months; P = 0.004). In multivariate analysis including stage and thrombocyte count, hypermethylation of ≥1 genes was an independent negative prognostic factor (P < 0.05). These data suggest that hypermethylation of p15INK 4 B, HIC1, CDH1, and ER contribute to the development and outcome of MDS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Frommer, M., McDonald, L. E., Millar, D. S., Collis, C. M., Watt, F., Grigg, G. W., Molloy, P. L., & Paul, C. L. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1827 · Cited by 3,238
Cited by
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
Jiang, Y., Dunbar, A., Gondek, L. P., Mohan, S., Rataul, M., O'Keefe, C., Sekeres, M., Saunthararajah, Y., & Maciejewski, J. P. (2009) · Blood · doi:10.1182/blood-2008-06-163246 · Cited by 384
GRØNBÆK, K., HOTHER, C., & JONES, P. A. (2007) · APMIS · doi:10.1111/j.1600-0463.2007.apm_636.xml.x · Cited by 366
DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes
Shen, L., Kantarjian, H., Guo, Y., Lin, E., Shan, J., Huang, X., Berry, D., Ahmed, S., Zhu, W., Pierce, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4781 · Cited by 355
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
Figueroa, M. E., Skrabanek, L., Li, Y., Jiemjit, A., Fandy, T. E., Paietta, E., Fernandez, H., Tallman, M. S., Greally, J. M., Carraway, H., et al. (2009) · Blood · doi:10.1182/blood-2009-01-200519 · Cited by 325
INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions
Cánepa, E. T., Scassa, M. E., Ceruti, J. M., Marazita, M. C., Carcagno, A. L., Sirkin, P. F., & Ogara, M. F. (2007) · IUBMB Life · doi:10.1080/15216540701488358 · Cited by 312
Metadata
- Authors
- Aggerholm, A., Holm, M. S., Guldberg, P., Olesen, L. H., & Hokland, P.
- Venue
- European Journal of Haematology
- Publisher
- Wiley
- Published
- 2005-11-18
- Volume
- 76
- Issue
- 1
- Pages
- 23-32
- ISSN
- 0902-4441 (ISSN-L)
- 1600-0609
- OpenAlex
- W2008731424
- Cited by
- 176
- References
- 2
- FWCI
- 6.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Promoter hypermethylation of p15INK 4 B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early‐stage patients. https://app.cochat.ai/papers/10.1111/j.1600-0609.2005.00559.x
- The paper
- Aggerholm, A., Holm, M. S., Guldberg, P., Olesen, L. H., & Hokland, P. (2006). Promoter hypermethylation of p15INK 4 B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early‐stage patients. European Journal of Haematology. https://doi.org/10.1111/j.1600-0609.2005.00559.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.